De­nali’s $500M place­ment; Brain health start­up rais­es $26M

Plus, news about Healis Ther­a­peu­tics, NRx Phar­ma­ceu­ti­cals, and Nu­va­lent:

De­nali Ther­a­peu­tics’ $500M PIPE: The com­pa­ny is sell­ing near­ly 30 mil­lion shares at $17.06 apiece. Bak­er Broth­ers Life Sci­ences is the lead in­vestor in the PIPE, per SEC fil­ings, and will get a board seat. The fund­ing co­in­cides with De­nali say­ing it nabbed $12.5 mil­lion from a third par­ty last month for a LRRK2 pro­gram called BI­IB122; how­ev­er, De­nali will take the pro­gram for­ward alone in­to a Phase IIa tri­al. Bio­gen is con­tin­u­ing to run a Phase IIb tri­al, and the pair will com­mer­cial­ize the drug to­geth­er if it re­ceives FDA ap­proval. It pre­vi­ous­ly dis­con­tin­ued a Phase III study for the pro­gram last June. De­nali shares $DNLI rose rough­ly 10% pre­mar­ket on Tues­day. — Max Gel­man

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER